Changchun High & New Technology Industries Group Inc
SZSE:000661
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
85.24
136.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Changchun High & New Technology Industries Group Inc
Changchun High & New Technology Industries Group Inc. (CHT) emerged as a key player in China's burgeoning pharmaceutical and medical device sector. Founded in 1993, it has consistently ridden the wave of technological innovation to establish itself as a prominent figure in the field. Located in the heart of Changchun, a city known for its industrial prowess, CHT has meticulously built its reputation by focusing on biopharmaceuticals, particularly those aimed at combating chronic diseases such as diabetes and cardiovascular ailments. With a robust pipeline of products and a strategic partnership with global pharmaceutical companies, CHT crafts its narrative around innovation and accessibility, striving to bring advanced healthcare solutions to a wider Chinese audience.
The company's business model thrives on a dual approach: leveraging cutting-edge research and a solid manufacturing base. By investing heavily in research and development, CHT fuels the continual advancement of its pharmaceutical and medical product lines. Its revenues are predominantly drawn from two sources—pharmaceutical sales and medical device manufacturing, with the latter seeing a surge due to an increased demand for modern healthcare solutions in China. This strategic focus allows CHT not only to expand its domestic market footprint but also to push toward international arenas, positioning itself as a competitive global entity in the healthcare ecosystem. Through agile adaptation to market needs and steadfast adherence to quality, CHT continues to write its growth story in an industry marked by rapid transformation and intense competition.
Changchun High & New Technology Industries Group Inc. (CHT) emerged as a key player in China's burgeoning pharmaceutical and medical device sector. Founded in 1993, it has consistently ridden the wave of technological innovation to establish itself as a prominent figure in the field. Located in the heart of Changchun, a city known for its industrial prowess, CHT has meticulously built its reputation by focusing on biopharmaceuticals, particularly those aimed at combating chronic diseases such as diabetes and cardiovascular ailments. With a robust pipeline of products and a strategic partnership with global pharmaceutical companies, CHT crafts its narrative around innovation and accessibility, striving to bring advanced healthcare solutions to a wider Chinese audience.
The company's business model thrives on a dual approach: leveraging cutting-edge research and a solid manufacturing base. By investing heavily in research and development, CHT fuels the continual advancement of its pharmaceutical and medical product lines. Its revenues are predominantly drawn from two sources—pharmaceutical sales and medical device manufacturing, with the latter seeing a surge due to an increased demand for modern healthcare solutions in China. This strategic focus allows CHT not only to expand its domestic market footprint but also to push toward international arenas, positioning itself as a competitive global entity in the healthcare ecosystem. Through agile adaptation to market needs and steadfast adherence to quality, CHT continues to write its growth story in an industry marked by rapid transformation and intense competition.
